RVPH Quote, Financials, Valuation and Earnings

Applied Therapeutics has a net margin of -- compared to Reviva Pharmaceuticals Holdings's net margin of -56222.13%. Reviva Pharmaceuticals Holdings's return on equity of -- beat Applied Therapeutics's return on equity of -797.82%.

Reviva Pharmaceuticals Holdings has a consensus price target of $14.80, signalling upside risk potential of 731.46%. On the other hand Applied Therapeutics has an analysts' consensus of $6.80 which suggests that it could grow by 594.77%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Applied Therapeutics, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Applied Therapeutics.

Reviva Pharmaceuticals Holdings has a beta of -0.023, which suggesting that the stock is 102.311% less volatile than S&P 500. In comparison Applied Therapeutics has a beta of 1.765, suggesting its more volatile than the S&P 500 by 76.451%.

Reviva Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings pays -- of its earnings as a dividend. Applied Therapeutics pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Applied Therapeutics quarterly revenues of $122K. Reviva Pharmaceuticals Holdings's net income of -$8.4M is higher than Applied Therapeutics's net income of -$68.6M. Notably, Reviva Pharmaceuticals Holdings's price-to-earnings ratio is -- while Applied Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings is -- versus -- for Applied Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Lipocine has a net margin of -- compared to Reviva Pharmaceuticals Holdings's net margin of -3426.15%. Reviva Pharmaceuticals Holdings's return on equity of -- beat Lipocine's return on equity of -36.41%.

Reviva Pharmaceuticals Holdings has a consensus price target of $14.80, signalling upside risk potential of 731.46%. On the other hand Lipocine has an analysts' consensus of -- which suggests that it could grow by 338.95%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Lipocine, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Lipocine.

Reviva Pharmaceuticals Holdings has a beta of -0.023, which suggesting that the stock is 102.311% less volatile than S&P 500. In comparison Lipocine has a beta of 1.240, suggesting its more volatile than the S&P 500 by 24.005%.

Reviva Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lipocine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings pays -- of its earnings as a dividend. Lipocine pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Lipocine quarterly revenues of $89.6K. Reviva Pharmaceuticals Holdings's net income of -$8.4M is lower than Lipocine's net income of -$2.2M. Notably, Reviva Pharmaceuticals Holdings's price-to-earnings ratio is -- while Lipocine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings is -- versus 5.45x for Lipocine. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Reviva Pharmaceuticals Holdings's net margin of 25.23%. Reviva Pharmaceuticals Holdings's return on equity of -- beat Pfizer's return on equity of 4.63%.

Reviva Pharmaceuticals Holdings has a consensus price target of $14.80, signalling upside risk potential of 731.46%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Pfizer, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Pfizer.

Reviva Pharmaceuticals Holdings has a beta of -0.023, which suggesting that the stock is 102.311% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Reviva Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Reviva Pharmaceuticals Holdings pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Reviva Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Reviva Pharmaceuticals Holdings's net income of -$8.4M is lower than Pfizer's net income of $4.5B. Notably, Reviva Pharmaceuticals Holdings's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings is -- versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Verastem has a net margin of -- compared to Reviva Pharmaceuticals Holdings's net margin of -82.56%. Reviva Pharmaceuticals Holdings's return on equity of -- beat Verastem's return on equity of -120.71%.

Reviva Pharmaceuticals Holdings has a consensus price target of $14.80, signalling upside risk potential of 731.46%. On the other hand Verastem has an analysts' consensus of -- which suggests that it could grow by 185.26%. Given that Reviva Pharmaceuticals Holdings has higher upside potential than Verastem, analysts believe Reviva Pharmaceuticals Holdings is more attractive than Verastem.

Reviva Pharmaceuticals Holdings has a beta of -0.023, which suggesting that the stock is 102.311% less volatile than S&P 500. In comparison Verastem has a beta of 0.221, suggesting its less volatile than the S&P 500 by 77.906%.

Reviva Pharmaceuticals Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Reviva Pharmaceuticals Holdings pays -- of its earnings as a dividend. Verastem pays out -- of its earnings as a dividend.

Reviva Pharmaceuticals Holdings quarterly revenues are --, which are smaller than Verastem quarterly revenues of $10M. Reviva Pharmaceuticals Holdings's net income of -$8.4M is higher than Verastem's net income of -$24M. Notably, Reviva Pharmaceuticals Holdings's price-to-earnings ratio is -- while Verastem's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Reviva Pharmaceuticals Holdings is -- versus -- for Verastem. Usually stocks with elevated PS ratios are considered overvalued.